Envoy Medical GAAP EPS of -$1.23, revenue of $0.02M

Envoy Medical reports catastrophic fundamental metrics: GAAP EPS of -$1.23 against revenue of only $0.02M represents a loss-to-revenue ratio that is essentially infinite, signaling a pre-commercial stage company burning cash with no visible path to near-term profitability. The revenue figure of $20,000 is so negligible it suggests either a commercial launch delay, severe reimbursement issues with the Acclaim Cochlear Implant, or near-total absence of market traction. Operating burn at this scale relative to revenue implies the company is entirely dependent on external capital raises, making dilution not just probable but mathematically inevitable for survival. The combination of near-zero topline and significant per-share losses places this squarely in distressed pre-revenue territory with binary outcome risk — either pipeline de-risking event or capital structure collapse. L2 bearish signal at -75 with 85% confidence aligns precisely with the quantitative data, reinforcing conviction in the downside thesis. ⚡ DEEP SONNET: For short exposure: wait for any technical bounce toward resistance or post-earnings dead-cat relief rally, ideally 10-15% above current levels; avoid chasing downside on day-of-print due to thin float volatility. For avoidance: immediate | TP:35% SL:20% | 2-4 months until next capital raise or catalytic event forces resolution | Risk:HIGH — Multiple compounding risks: (1) imminent dilutive capital raise near-certain given burn rate vs. cash position, (2) reimbursement uncertainty for Acclaim implant limiting commercial ramp, (3) micro-float creates short-squeeze tail risk making timing of short entries dangerous, (4) potential for reverse stock split masking deterioration, (5) low liquidity amplifies bid-ask spread costs on any position | Sizing:CONSERVATIVE — micro-float short squeeze risk demands strictly limited position size; maximum 0.5-1% portfolio exposure if shorting; borrow costs and squeeze risk make standard sizing inappropriate